Trial Demonstrates Positive Long-Term Efficacy and Safety for Migraine Drug

Amgen and Novartis have announced positive long-term efficacy, safety, and tolerability data of erenumab-aooe (Aimovig) in patients with chronic and episodic migraine.

Amgen and Novartis have announced positive long-term efficacy, safety, and tolerability data of erenumab-aooe (Aimovig) in patients with chronic and episodic migraine.

According to the pharmaceutical companies, the calcitonin gene-related peptide (CGRP) inhibitor has demonstrated efficacy and safety in a 1-year study in chronic migraine and reinforced safety and tolerability in a 3-year interim analysis from an ongoing 5-year study in episodic migraine.

“On the heels of the recent FDA approval of Aimovig for the preventive treatment of migraine in adults, the results of these open-label extension studies are encouraging as they contribute to a growing and extensive body of evidence that support the use of Aimovig across the spectrum of migraine, said Sean E. Harper, MD, executive vice president, research and development, Amgen, in a statement.

Click to continue reading on The American Journal of Managed Care.